scispace - formally typeset
S

Shigehiro Katayama

Researcher at Saitama Medical University

Publications -  251
Citations -  11344

Shigehiro Katayama is an academic researcher from Saitama Medical University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 49, co-authored 251 publications receiving 10637 citations.

Papers
More filters
Journal ArticleDOI

Clinical significance of ambulatory blood pressure monitoring. Evaluation of severity of hypertension, efficacy of treatment and effects on nighttime blood pressure.

TL;DR: The results suggest that simple ABP monitoring throughout the day gives useful information to evaluate the severity of hypertension and the efficacy of antihypertensive medication as well as to avoid overtreatment with long-acting hypotensive agents resulting in a great fall in BP during sleep.
Journal ArticleDOI

High glucose concentration suppresses mesangial laminin B2 gene expression.

TL;DR: It is suggested that the decrease of laminin B2 mRNA during hyperglycemia or exposure to high osmolarity may have some pathophysiologic significance in the development of diabetic nephropathy.
Journal ArticleDOI

Higher Dietary Intake of Vitamin D Is Associated with Lower Incidence of Diabetic Nephropathy in Japanese Patients with Type 2 Diabetes

TL;DR: It is suggested that high vitamin D intake was associated with a lower incidence of diabetes nephropathy among Japanese patients with type 2 diabetes.
Journal ArticleDOI

Elevated erythrocyte sodium-lithium counter-transport in hypertensive patients with non-insulin-dependent diabetes mellitus.

TL;DR: An increase of Na-Li CT may not be due to the stimulatory effect of endogenous or exogenous insulin, and reflect a genetic predisposition for hypertension, and hence diabetic nephropathy, not only in IDDM but also NIDDM patients.
Journal ArticleDOI

Effect of alpha1-blockade on diminished forearm blood flow in diabetics

TL;DR: It is suggested that FBF may be a simple and useful index for determining arterial and/or venous distensibility, and that alpha 1-blocker therapy, in addition to glycemic control, mayBe a first-line antihypertensive treatment for diabetics with associated hypertension.